
AMGXF
Healthcare · Biotechnology · $143.7M market cap
$0.36020.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 9, 2023 | After the close | — | -27.39 | — |
| Nov 7, 2022 | After the close | — | -18.09 | — |
| Aug 8, 2022 | After the close | — | -29.32 | — |
| May 9, 2022 | After the close | — | -19.19 | — |
| Feb 9, 2022 | After the close | — | -11.25 | — |
| Nov 4, 2021 | After the close | — | -29.39 | — |
| Aug 5, 2021 | After the close | — | -27.71 | — |
| May 9, 2021 | After the close | 0.00 | -0.25 | — |
| Feb 14, 2021 | After the close | 0.00 | -8.28 | — |
| Oct 25, 2020 | After the close | — | -10.39 | — |
| Jul 29, 2020 | After the close | — | -8.06 | — |
| Apr 27, 2020 | Time not confirmed | — | -8.56 | — |
| Feb 2, 2020 | After the close | — | -9.16 | — |
| Oct 27, 2019 |
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc.…
| After the close |
| 0.00 |
| -0.08 |
| — |
| Jul 28, 2019 | After the close | 0.00 | -0.07 | — |
| Apr 21, 2019 | After the close | 0.00 | -0.07 | — |
| Jan 31, 2019 | After the close | — | -8.37 | — |
| Oct 28, 2018 | After the close | — | -11.86 | — |
| Jul 29, 2018 | After the close | 0.00 | -0.10 | — |
| Apr 22, 2018 | After the close | 0.00 | -0.07 | — |
| Feb 1, 2018 | After the close | — | -5.12 | — |